|Bid||10.5600 x 1000|
|Ask||11.1200 x 900|
|Day's range||10.5900 - 10.6700|
|52-week range||6.9800 - 31.5900|
|PE ratio (TTM)||N/A|
|Earnings date||7 Aug 2017 - 11 Aug 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||17.14|
On a per-share basis, the Menlo Park, California-based company said it had a loss of $1.42. Losses, adjusted for asset impairment costs, were $1.39 per share. The skin condition drug developer posted revenue ...
Key announcements include the failure of Dermira's (DERM) acne candidate in two pivotal late-stage studies and Merck's oncology collaboration with Japan's Eisai.
Dermira's (DERM) pipeline candidate, olumacostat glasaretil, fails to meet primary endpoints in two pivotal studies, which evaluate its efficacy for treating moderate-to-severe acne vulgaris.
Dermira crashed more than 60% early Monday after announcing a pair of acne trials failed in Phase 3 testing.
U.S. stocks swung higher on Monday as investors said they were expecting U.S. President Donald Trump to back down on his threat to impose hefty tariffs on steel and aluminum imports. The three major U.S. equity indexes rose on bets the threat was just a negotiating tool after Trump said Canada and Mexico could avoid his proposed tariffs if they ceded ground on the North American Free Trade Agreement. Also U.S. House Speaker Paul Ryan urged the administration not to move forward on the tariffs, citing risks to the economy.
The Menlo Park, California-based company said it had a loss of $1.34 per share. The skin condition drug developer posted revenue of $1.3 million in the period. For the year, the company reported that its ...
The Menlo Park, California-based company said it had a loss of $4.30 per share. Losses, adjusted for costs related to mergers and acquisitions, came to $1.21 per share. The skin condition drug developer ...